Rupam Manna, Medical Oncologist, Entrepreneur, interested in Metabolism education and brain science, shared a post on X:
“Neo-RAS: When a “RAS-mutant” tumor becomes RAS wild-type!
Did you know that some patients with metastatic colorectal cancer can regain eligibility for anti-EGFR therapy after initially being RAS-mutant?
- Treatment pressure can suppress RAS-mutant clones.
- ctDNA (liquid biopsy) may then reveal Neo-RAS (RAS conversion).
- Carefully selected patients may benefit from cetuximab or panitumumab rechallenge, as demonstrated in studies such as the CHRONOS trial.
This is a fascinating example of how tumor evolution and precision oncology are changing treatment decisions in metastatic colorectal cancer.
What was once considered resistant may become targetable again.”
Other articles about Metastatic Colorectal Cancer on OncoDaily.